TRIAL DETAIL
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 07/01/2005 |
Age of Trial (yrs) 18.8 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
HDAC inhibitor + Proteasome inhibitor |
|||
Strategy: |
Inhibit protein translation + Unblock cell death genes |
|||
Trial Type: |
GIST not specified. GIST patients known to be enrolled. |
|||
Other Protocol IDs: |
CDR0000441195, WCCC-CO-04906, NCI-6910 |
|||
Sponsor: |
University of Wisconsin, Madison
NCI |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral
Intravenous |
|||
Trial Notes: |
This trial has admitted three GIST patients. Non-durable stable is best response to date. |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Madison |
WI |
53792 |
USA |